<DOC>
	<DOCNO>NCT01258387</DOCNO>
	<brief_summary>Study determine safety , tolerability , pharmacokinetics immunogenicity single intravenous administration GGF2 patient heart failure .</brief_summary>
	<brief_title>Single Ascending Doses GGF2 Patients With Left Ventricular Dysfunction Symptomatic Heart Failure</brief_title>
	<detailed_description>Phase 1 , double-blind , placebo-controlled , dose escalation study determine safety , tolerability , pharmacokinetics immunogenicity single intravenous administration GGF2 cohorts patient leave ventricular dysfunction symptomatic heart failure .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>1 . Left ventricular ejection fraction ( LVEF ) 10 % 40 % . 2 . Male female , age 18 75 year , inclusive . 1 . Received investigational agent participation clinical study investigational agent investigational therapy 30 day prior screen visit . 2 . Use new prescription medication 14 day prior receive investigational drug . 3 . Patients know specific hepatic disease ; bilirubin &gt; 2 mg/dL , SGOT &gt; 100 IU . 4 . Patients history hepatic impairment ( hepatitis B C ) . 5 . Serum creatinine &gt; 2.5 mg/dL . 6 . Documented stroke transient ischemic attack ( TIA ) within 60 day study enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>